Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index; 4 of the 21 sources its claims cite were checked for support.
Abstract
Background Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after blood and marrow transplantation. We aimed to compare the efficacy and safety of intravenous rezafungin versus intravenous caspofungin in patients with candidaemia and invasive candidiasis.Methods ReSTORE was a multicentre, double-blind, double-dummy, randomised phase 3 trial done at 66 tertiary care centres in 15 countries. Adults (≥18 years) with systemic signs and mycological confirmation of candidaemia or invasive candidiasis were eligible for inclusion and randomly assigned (1:1) to receive intravenous rezafungin once a week (400 mg in week 1, followed by 200 mg weekly, for a total of two to four doses) or intravenous caspofungin (70 mg loading dose on day 1, followed by 50 mg daily) for no more than 4 weeks. The primary endpoints were global cure (consisting of clinical cure, radiological cure, and mycological eradication) at day 14 for the European Medical Agency (EMA) and 30-day all-cause mortality for the US Food and Drug Administration (FDA), both with a target non-inferiority margin of 20%, assessed in the modified intention-to-treat population (all patients who received one or more doses of study drug and had documented Candida infection based on a culture from blood or another normally sterile site obtained within 96 h before randomisation). Safety was evaluated by the incidence and type of adverse events and deaths in the safety population, defined as all patients who received any amount of study drug. The trial is registered with ClinicalTrials.gov, NCT03667690, and is complete.Findings Between Oct 12, 2018, and Aug 29, 2021, 222 patients were screened for inclusion, and 199 patients (118 [59%] men; 81 [41%] women; mean age 61 years [SD 15·2]) were randomly assigned (100 [50%] patients to the rezafungin group and 99 [50%] patients to the caspofungin group). 55 (59%) of 93 patients in the rezafungin group and 57 (61%) of 94 patients in the caspofungin group had a global cure at day 14 (weighted treatment difference -1·1% [95% CI -14·9 to 12·7]; EMA primary endpoint). 22 (24%) of 93 patients in the rezafungin group and 20 (21%) of 94 patients in the caspofungin group died or had an unknown survival status at day 30 (treatment difference 2·4% [95% CI -9·7 to 14·4]; FDA primary endpoint). In the safety analysis, 89 (91%) of 98 patients in the rezafungin group and 83 (85%) of 98 patients in the caspofungin group had at least one treatment-emergent adverse event. The most common treatment-emergent adverse events that occurred in at least 5% of patients in either group were pyrexia, hypokalaemia, pneumonia, septic shock, and anaemia. 55 (56%) patients in the rezafungin group and 52 (53%) patients in the caspofungin group had serious adverse events.Interpretation Our data show that rezafungin was non-inferior to caspofungin for the primary endpoints of day-14 global cure (EMA) and 30-day all-cause mortality (FDA). Efficacy in the initial days of treatment warrants evaluation. There were no concerning trends in treatment-emergent or serious adverse events. These phase 3 results show the efficacy and safety of rezafungin and support its ongoing development.Funding Cidara Therapeutics and Mundipharma.
Overview
CoChat Summary
TL;DR
In the phase 3 ReSTORE trial, once-weekly rezafungin was non-inferior to daily caspofungin for treating candidaemia and invasive candidiasis on both the EMA day-14 global cure and FDA 30-day all-cause mortality endpoints. Safety profiles were similar between groups.
Key findings
- In the modified intention-to-treat population, day-14 global cure occurred in 55/93 (59%) rezafungin patients vs 57/94 (61%) caspofungin patients; weighted treatment difference −1·1% (95% CI −14·9 to 12·7), with the lower CI bound above the −20% non-inferiority margin.
- 30-day all-cause mortality was 22/93 (24%) with rezafungin vs 20/94 (21%) with caspofungin; treatment difference 2·4% (95% CI −9·7 to 14·4), with the upper CI bound below the 20% non-inferiority margin.
- Treatment-emergent adverse events occurred in 89/98 (91%) rezafungin patients vs 83/98 (85%) caspofungin patients; serious adverse events occurred in 55/98 (56%) vs 52/98 (53%), and drug-related adverse events in 16% vs 9%.
- Exploratory early outcomes showed negative blood cultures at 24 h in 36/67 (54%) rezafungin vs 30/65 (46%) caspofungin patients and at 48 h in 49/66 (74%) vs 41/64 (64%); median time to negative blood culture was 23·9 h vs 27·0 h (p=0·18).
Methods
- Multicentre, double-blind, double-dummy, randomised phase 3 non-inferiority trial at 66 tertiary care centres in 15 countries; adults aged ≥18 years with systemic signs and mycological confirmation of candidaemia or invasive candidiasis were randomised 1:1, with 199 patients assigned (100 rezafungin, 99 caspofungin).
- Rezafungin was given intravenously once weekly (400 mg in week 1, then 200 mg weekly, for two to four doses); caspofungin was given intravenously (70 mg loading dose on day 1, then 50 mg daily) for no more than 4 weeks, with optional oral step-down fluconazole in the caspofungin group and matching placebo in the rezafungin group.
- Primary endpoints were EMA-mandated day-14 global cure and FDA-mandated 30-day all-cause mortality, both with a 20% non-inferiority margin and assessed in the modified intention-to-treat population; safety was assessed in the safety population, with Miettinen-Nurminen CIs and SAS analyses.
Limitations
- The paper states that paediatric patients and patients with certain forms of candidiasis were excluded, including forms requiring long antifungal courses (e.g., biofilm-related invasive candidiasis) or occurring at sites with poor echinocandin penetration (e.g., urinary tract and CNS); safety was also not studied in severe hepatic impairment because of the caspofungin contraindication.
- Evident from the text: the trial was designed as a non-inferiority study, so it cannot establish superiority of rezafungin over caspofungin; subgroup and exploratory analyses, including early efficacy outcomes, were not the primary basis for inference.
- Evident from the text: the trial enrolled a specific adult population with mostly candidaemia and excluded several complicated forms of invasive candidiasis, so generalisability to those excluded populations is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 9 Not checked · 50 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, pharmacokinetic data and results of a phase 1 trial of rezafungin in hepatic impairment support no rezafungin dose adjustment. 28”
What the sources say
- Supportedcites [28] Huguet, 2021, 982. Effect of hepatic impairment on the safety and pharmacokinetics of rezafungin, Open Forum Infect Dis source
The Conclusion of our copy states verbatim that rezafungin 'was well tolerated in HI subjects and showed modestly reduced exposure that was within the range observed in matched HS. These findings support no RZF dose adjustment in subjects with severe hepatic impairment.' The Methods and Results supply exactly the PK data attributed (single 400-mg IV infusion, 8 severe-HI and 8 matched healthy subjects, Cmax/AUC ~30% lower, similar half-life ~121 vs 124 h), and the Background describes it as an open-label single-dose study in Child-Pugh class C HI — i.e., the phase 1-type hepatic-impairment trial the citing sentence refers to. The only narrowing relative to the claim is that the source's conclusion is scoped to severe (Child-Pugh C) impairment rather than impairment in general, and it does not itself use the label 'phase 1'; the substance of the attribution is nonetheless stated. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“30-day all-cause mortality rates were similar between treatment groups when evaluated in subgroups defined by patient age, sex, race, geographical region, or modified APACHE II score or ANC at randomisation (appendix p 18).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the safety analysis, 89 (91%) of 98 patients in the rezafungin group and 83 (85%) of 98 patients in the caspofungin group had at least one treatment-emergent adverse event.”
plainn = 98- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, the observed treatment difference in mycological eradication at day 5 in patients with candidaemia was 78% in the rezafungin group and 69% in the caspofungin group (table 3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Other key secondary efficacy outcomes, including global cure at day 30, end of treatment, and follow-up, were also similar between treatment groups.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
20 more claims
Create a free account to see all 61 claims and to verify the 17 references still open.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Encouragingly, a new echinocandin, rezafungin, was approved by the Food and Drug Administration in 2023 for adults with invasive fungal infections after ReSTORE, a Phase 3 clinical trial comparing it to caspofungin for treatment of invasive candidiasis, demonstrated non-inferiority and a 60% cure rate.154,155”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [155]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Encouragingly, a new echinocandin, rezafungin, was approved by the Food and Drug Administration in 2023 for adults with invasive fungal infections after ReSTORE, a Phase 3 clinical trial comparing it to caspofungin for treatment of invasive candidiasis, demonstrated non-inferiority and a 60% cure rate.154,155”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [155]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“14 [26%] of 53 patients in the rezafungin group vs 13 [34%] of 38 patients in the caspofungin group; treatment difference -6·8% [-26·2 to 12·7]”
Reported -6.8 · recomputed -8
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“14 (28%) of 51 patients in the caspofungin group with candidaemia and a catheter present at screening had catheter removal within 48 h of diagnosis.”
Reported 28 · recomputed 27.45098
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Summary · p. 2
“199 patients (118 [59%] men; 81 [41%] women; mean age 61 years [SD 15·2])”
§ Figure 1: Trial profile · p. 7
“| Male | 67 (67%) | 56 (57%) | | Female | 33 (33%) | 43 (43%) |”
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationPappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Self-citationGarey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
Anidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Self-citationKuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Self-citationMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationSeptic shock attributed to Candida infection: Importance of empiric therapy and source control.
Kollef, M., Micek, S., Hampton, N., Doherty, J. A., & Kumar, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis305 · Cited by 477
Self-citationEstimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
Research works printed but not linked: 1
- Adeel, 2021, Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: a case report, Open Forum Infect Dis, 8
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Self-citationLass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
Self-citationAntifungal Drug Resistance: An Emergent Health Threat
Vitiello, A., Ferrara, F., Boccellino, M., Ponzo, A., Cimmino, C., Comberiati, E., Zovi, A., Clemente, S., & Sabbatucci, M. (2023) · Biomedicines · doi:10.3390/biomedicines11041063 · Cited by 228
Invasive candidiasis: current clinical challenges and unmet needs in adult populations
Soriano, A., Honore, P. M., Puerta-Alcalde, P., Garcia-Vidal, C., Pagotto, A., Gonçalves-Bradley, D. C., & Verweij, P. E. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad139 · Cited by 190
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 184
Self-citation
Metadata
- Authors
- Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., Poromanski, I., Dignani, C., Das, A. F., Sandison, T., Pappas, P. G., Akova, M., AlAgha, R., Alangaden, G., Albrecht, S. J., Alexander, B., Al-Obaidi, M., Ambasch, G., Armestar Rodriguez, F., Azap, A., Baffoe-Bonnie, A., Belkhir, L., Ben-Ami, R., Boutoille, D., Cascio, A., Chai, L. Y., Chaiwarith, R., Chayakulkeeree, M., Chen, S., Chen, Y.-C., Chen, Y.-H., Choi, J. Y., Choi, Y. H., Chotiprasitsakul, D., Chung, J. W., Danion, F., Denis, B., Diaz Santos, E., Dictar, M. O., Diltoer, M., Dupont, H., Feng, S., Ferre Colomer, M. A., Ferrer, R., Forel, J.-M. F. R., Fortún-Abete, J., Garcia-Diaz, J., Girardis, M., He, F., Hites, M., Ho, M.-W., Honore, P., Horcajada Gallego, J. P., Huang, H., Huang, P.-Y., Huang, Y., Hussein, O., Intalapaporn, P., Jaruratanasirikul, S., Jauregui-Peredo, L., Johnson, M., Jung, D. S., Jutivorakool, K., Kern, W. V., Kett, D. H., Khawcharoenporn, T., Kim, Y. K., Koehler, P., Kotanidou, A., Lachiewicz, A., Lin, Q., Lopez Cortes, L. E., Luo, H., Luzzati, R., Maor, Y., McCarty, T., Merelli, M., Merino Amador, P., Midturi, J., Migliorino, G. M., Mira, J.-P., Mootsikapun, P., Morrissey, O., Munoz Garcia de Paredes, P., Mussini, C., Mylonakis, E., Nseir, S., Nseir, W., Odabasi, Z., Papastamopoulos, V., Paterson, D., Patterson, T. F., Peck, K. R., Peng, Z., Permpalung, N., Plantefeve, G. J., Poromanski, I. G., Powell, D., Psichogiou, M., Puah, S. H., Pullman, J., Rahav, G., Martinez, A. R., Ramos Ramos, J. C., Raz-Pasteur, A., Restrepo Castro, C. A., Riera, F., Roblot, F., Rodriguez Alvarez, R. J., Rogers, B., Roilides, E., Sanchez Vallejo, G., Sganga, G., Sipsas, N., Slavin, M., Soriano, A., Spec, A., Strahilevitz, J., Tancheva, D. M., Tao, Z., Teschner, D., Thompson, G. R., Van Wijngaerden, E., Vazquez, J., Vergidis, P., Viale, P., Wang, F.-D., Wang, S., Weber, G., Weng, J., Xu, J., Yao, L., Yavuz, S., Yilmaz, M., Young, J.-A., Zarate, A. H., Zeng, J., & Zhang, Y.
- Affiliations
- University of Cologne (DE)
- Radboud University Medical Center (NL)
- Washington University in St. Louis (US)
- Ospedale Policlinico San Martino (IT)
- Cidara Therapeutics (United States) (US)
- University of Alabama at Birmingham (US)
- University of California Davis Medical Center (US)
- Siriraj Hospital (TH)
- Université Libre de Bruxelles (BE)
- ORCID
- Cornely, Oliver A
- Kullberg, Bart Jan
- Kollef, Marin
- Bassetti, Matteo
- Pappas, Peter G
- Akova, Murat
- AlAgha, Rawan
- Alangaden, George
- Alexander, Barbara
- Azap, Alpay
- Baffoe-Bonnie, Anthony
- Boutoille, David
- Cascio, Antonio
- Chaiwarith, Romanee
- Chen, Yee-Chun
- Chen, Yen-Hsu
- Choi, Jun Yong
- Choi, Young Hwa
- Chotiprasitsakul, Darunee
- Chung, Jin Won
- Danion, François
- Denis, Blandine
- Feng, Sizhou
- Ferrer, Ricard
- Forel, Jean-Marie Fernand Roger
- Girardis, Massimo
- He, Fang
- Hites, Maya
- Huang, Haihui
- Huang, Po-Yen
- Huang, Yong
- Jaruratanasirikul, Sutep
- Jung, Dong Sik
- Kern, Winfried V
- Khawcharoenporn, Thana
- Kim, Young Keun
- Koehler, Philipp
- Kotanidou, Anastasia
- Lachiewicz, Anne
- Luo, Hong
- Luzzati, Roberto
- McCarty, Todd
- Merelli, Maria
- Midturi, John
- Migliorino, Guglielmo Marco
- Mira, Jean-Paul
- Mootsikapun, Piroon
- Mussini, Cristina
- Mylonakis, Eleftherios
- Nseir, William
- Papastamopoulos, Vasileios
- Paterson, David
- Patterson, Thomas F
- Peck, Kyong Ran
- Peng, Zhiyong
- Permpalung, Nitipong
- Puah, Ser Hon
- Rahav, Galia
- Riera, Fernando
- Roblot, France
- Rogers, Benjamin
- Roilides, Emmanuel
- Sganga, Gabriele
- Sipsas, Nikolaos
- Slavin, Monica
- Spec, Andrej
- Strahilevitz, Jacob
- Teschner, Daniel
- Vergidis, Paschalis
- Viale, Pierluigi
- Wang, Fu-Der
- Wang, Shifu
- Yavuz, Serap
- Young, Jo-Anne
- Zeng, Jun
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 401
- Issue
- 10370
- Pages
- 49-59
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4309967380
- Cited by
- 192
- References
- 28
- Citations by year
- 2026: 47 · 2025: 54 · 2024: 59 · 2023: 30
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Cidara Therapeutics
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- caspofungin, candidemia, invasive candidiasis, echinocandins, antifungal therapy, non-inferiority, 30-day mortality, adverse events, fungal infection treatment, double-dummy design, RESTORE trial, Candida
- MeSH terms
- Caspofungin, Adult, Candidiasis, Double-Blind Method, Female, Humans, Male, Middle Aged, Treatment Outcome, Echinocandins, Candidiasis, Invasive, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02324-8
- The paper
- Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., Poromanski, I., Dignani, C., Das, A. F., Sandison, T., Pappas, P. G., Akova, M., AlAgha, R., Alangaden, G., Albrecht, S. J., . . . Zhang, Y. (2023). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02324-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.